European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 19 · Tue 20 Oct 

Deals

Who bought what in European psychedelic medicine, and what the filings say they paid.

0$1bn$2bn$3bn$4bn13 May 202415 Oct 202620252026$0.22mEuropean Commission / NUDZ$3.8bnLilly / AtaiBeckley$1.2bnOtsuka / Transcend$1.2bnAbbVie / Gilgamesh 2025atai / Beckley Psytech$2bnAbbVie / Gilgamesh 2024

Every deal we track, when it was announced and what it was worth.

Height is the headline dollar value. Hollow means no dollar price.

grant

European Commission Narodni ustav dusevniho zdravi

Announced
1 September 2026
Upfront
$0.22m
Headline total
$0.22m
Value basis
EUR 191918.16 EU contribution
Status
active
Lead asset
none (preclinical circuitry research, psychedelics unspecified)

No dollar price in the agreement.

Open deal

acquisition

Eli Lilly and Company AtaiBeckley Inc.

Announced
16 July 2026
Upfront
$2.8bn
Contingent
$1bn
Headline total
$3.8bn
Value basis
USD
Status
closed
Lead asset
BPL-003 (mebufotenin benzoate)
Upfront
$2.8bn
Contingent
$1bn

Paid at closing, and what depends on milestones.

Open deal

acquisition

Otsuka Pharmaceutical Co., Ltd. (through wholly owned subsidiary Otsuka America, Inc.) Transcend Therapeutics, Inc.

Announced
27 March 2026
Upfront
$700m
Contingent
$525m
Headline total
$1.2bn
Value basis
USD
Status
closed
Lead asset
TSND-201 (methylone)
Upfront
$700m
Contingent
$525m

Paid at closing, and what depends on milestones.

Open deal

acquisition

AbbVie Inc. Gilgamesh Pharmaceuticals, Inc.

Announced
25 August 2025
Upfront
$906m
Contingent
$300m
Headline total
$1.2bn
Value basis
USD
Status
closed
Lead asset
bretisilocin (GM-2505, renamed ABBV-2505)
Upfront
$906m
Contingent
$300m

Paid at closing, and what depends on milestones.

Open deal

acquisition

atai Life Sciences N.V. (renamed Atai Beckley N.V. on completion) Beckley Psytech Limited

Announced
2 June 2025
Value basis
ordinary shares (all-share consideration, no cash)
Status
closed
Lead asset
BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate); second asset ELE-101 (psilocin)

No dollar price in the agreement.

Open deal

collaboration and option-to-license

AbbVie Inc. Gilgamesh Pharmaceuticals, Inc. (agreement transferred to Gilgamesh Pharma Inc. at the 2025 spin-out)

Announced
13 May 2024
Upfront
$65m
Contingent
$1.95bn
Headline total
$2bn
Value basis
USD
Status
active
Lead asset
not named (next-generation neuroplastogen portfolio)
Upfront
$65m
Contingent
$1.95bn

Paid at closing, and what depends on milestones.

Open deal

DateTargetAcquirer or investorConsiderationSourceVerified
2026-09-01Narodni ustav dusevniho zdraviEuropean Commission$0.22m upfront = $0.22mcordis.europa.eu2026-09-28
2026-07-16AtaiBeckley Inc.Eli Lilly and Company$2.8bn upfront + $1bn contingent = $3.8bnsec.gov2026-10-06
2026-03-27Transcend Therapeutics, Inc.Otsuka Pharmaceutical Co., Ltd. (through wholly owned subsidiary Otsuka America, Inc.)$700m upfront + $525m contingent = $1.2bnotsuka.co.jp2026-09-22
2025-08-25Gilgamesh Pharmaceuticals, Inc.AbbVie Inc.$906m upfront + $300m contingent = $1.2bnsec.gov2026-09-17
2025-06-02Beckley Psytech Limitedatai Life Sciences N.V. (renamed Atai Beckley N.V. on completion)all-sharesec.gov2026-10-07
2024-05-13Gilgamesh Pharmaceuticals, Inc. (agreement transferred to Gilgamesh Pharma Inc. at the 2025 spin-out)AbbVie Inc.$65m upfront + $1.95bn contingent = $2bnnews.abbvie.com2026-09-17